Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study.
Adherence
Aflibercept
Age-related macular degeneration
Long-term effect of compliance
Loss to follow-up
Persistence
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
19 Sep 2022
19 Sep 2022
Historique:
received:
20
08
2022
accepted:
07
09
2022
entrez:
19
9
2022
pubmed:
20
9
2022
medline:
23
9
2022
Statut:
epublish
Résumé
This study aimed to analyse the persistence rates of treatment-naïve patients with neovascular age-related macular degeneration (nAMD) who received intravitreal aflibercept therapy in a universal health care system. In this single-centre retrospective cohort study, we audited data of 918 treatment-naïve patients who received exclusively intravitreal aflibercept therapy for nAMD between September 2015 and May 2021. The primary outcome measures were the rates of treatment nonpersistence (gap in ophthalmological care > 6 months) and long-term nonpersistence (> 12 months). The rates of nonpersistence and long-term nonpersistence were 12.3% and 3.4% after one year; 22.4% and 9.5% after two years; and 38.3% and 19.3% after five years, respectively. Logistic regression analysis revealed that older age (p = 0.045), male sex (p = 0.039), requirement for caretakers or ambulance (p = 0.001), and low visual acuity of the study eye (p = 0.010) or fellow eye (p = 0.029) were independent risk factors for long-term nonpersistence. Patients aged > 80 and > 85 years (p = 0.013 and p = 0.022, respectively) had more than twice the risk for being nonpersistent to therapy within two years of follow-up compared with younger patients. Male patients (p = 0.033), patients requiring a caretaker (p = 0.038), and patients living > 60 km from the clinic (p = 0.029) had a 2 × higher risk of being persistently nonpersistent to therapy. Patients with nAMD who were treated with aflibercept had lower nonpersistence rates than those reported in current literature. Multiple independent risk factors were correlated with long-term nonpersistence, early nonpersistence, or complete loss to follow-up. Considering the possible consequences of reduced compliance, further strategies are urgently needed for patients at risk of nonpersistence to therapy.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to analyse the persistence rates of treatment-naïve patients with neovascular age-related macular degeneration (nAMD) who received intravitreal aflibercept therapy in a universal health care system.
METHODS
METHODS
In this single-centre retrospective cohort study, we audited data of 918 treatment-naïve patients who received exclusively intravitreal aflibercept therapy for nAMD between September 2015 and May 2021. The primary outcome measures were the rates of treatment nonpersistence (gap in ophthalmological care > 6 months) and long-term nonpersistence (> 12 months).
RESULTS
RESULTS
The rates of nonpersistence and long-term nonpersistence were 12.3% and 3.4% after one year; 22.4% and 9.5% after two years; and 38.3% and 19.3% after five years, respectively. Logistic regression analysis revealed that older age (p = 0.045), male sex (p = 0.039), requirement for caretakers or ambulance (p = 0.001), and low visual acuity of the study eye (p = 0.010) or fellow eye (p = 0.029) were independent risk factors for long-term nonpersistence. Patients aged > 80 and > 85 years (p = 0.013 and p = 0.022, respectively) had more than twice the risk for being nonpersistent to therapy within two years of follow-up compared with younger patients. Male patients (p = 0.033), patients requiring a caretaker (p = 0.038), and patients living > 60 km from the clinic (p = 0.029) had a 2 × higher risk of being persistently nonpersistent to therapy.
CONCLUSIONS
CONCLUSIONS
Patients with nAMD who were treated with aflibercept had lower nonpersistence rates than those reported in current literature. Multiple independent risk factors were correlated with long-term nonpersistence, early nonpersistence, or complete loss to follow-up. Considering the possible consequences of reduced compliance, further strategies are urgently needed for patients at risk of nonpersistence to therapy.
Identifiants
pubmed: 36123657
doi: 10.1186/s12886-022-02593-7
pii: 10.1186/s12886-022-02593-7
pmc: PMC9483893
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
372Informations de copyright
© 2022. The Author(s).
Références
Ophthalmology. 2014 Jan;121(1):193-201
pubmed: 24084500
Transl Vis Sci Technol. 2015 Jun 8;4(3):6
pubmed: 26069865
Ophthalmology. 2021 Feb;128(2):234-247
pubmed: 32763265
Klin Monbl Augenheilkd. 2022 Aug 04;:
pubmed: 35445380
Am J Ophthalmol. 2019 Dec;208:206-210
pubmed: 30905726
Turk J Ophthalmol. 2017 Aug;47(4):205-210
pubmed: 28845324
Adv Ther. 2020 Mar;37(3):1173-1187
pubmed: 32016788
Ophthalmologe. 2016 Nov;113(11):925-932
pubmed: 27272633
Ophthalmology. 2013 Nov;120(11):2292-9
pubmed: 23642856
Semin Ophthalmol. 2021 May 19;36(4):304-309
pubmed: 33764255
Surv Ophthalmol. 2013 Jul-Aug;58(4):348-58
pubmed: 23664105
Br J Ophthalmol. 2014 Sep;98(9):1144-67
pubmed: 25136079
Telemed J E Health. 2020 Apr;26(4):565-568
pubmed: 32209019
JAMA Ophthalmol. 2021 Jul 1;139(7):769-776
pubmed: 34081099
Graefes Arch Clin Exp Ophthalmol. 2013 May;251(5):1281-4
pubmed: 23086225
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
JAMA Ophthalmol. 2018 Nov 1;136(11):1251-1259
pubmed: 30352121
Ophthalmol Ther. 2021 Dec;10(4):935-945
pubmed: 34374028
Ophthalmology. 2010 May;117(5):921-7
pubmed: 20110127
Crit Rev Oncol Hematol. 2008 Aug;67(2):124-32
pubmed: 18375141
J Fr Ophtalmol. 2015 Sep;38(7):620-7
pubmed: 25913443
Med J Aust. 2005 Oct 3;183(7):366-8
pubmed: 16201955
Clin Ophthalmol. 2017 Dec 20;12:13-20
pubmed: 29339917
Br J Ophthalmol. 2015 Feb;99(2):220-6
pubmed: 25193672
Ophthalmology. 2008 Jan;115(1):116-26
pubmed: 17675159
Graefes Arch Clin Exp Ophthalmol. 2021 Jul;259(7):1773-1780
pubmed: 33977317